LogicBio Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

ContextLogic Holdings

07/03/2022 13:01

* LogicBio Therapeutics Inc  LOGC.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 34 cents per share.
    * Revenue rose 274% to $2.03 million from a year ago; 
analysts
expected $1.45 million. 
    * LogicBio Therapeutics Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * LogicBio Therapeutics Inc shares had fallen by 71.7% this
quarter.
    * The company reported a quarterly loss of $9.06 million.
    * Wall Street's median 12-month price target for LogicBio
Therapeutics Inc is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 7 at 01:01 p.m.  ​All
figures in US dollars unless otherwise stated